Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 7/20 | 0.79 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.79 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28368772 | 1.00 | PHGDH (0.79) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL20115438 | 0.88 | PHGDH (1.00) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL20115494 | 0.88 | PHGDH (0.67) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL21292810 | 0.88 | PHGDH (1.00) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28369229 | 0.86 | KEAP1 (0.85) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28369230 | 0.86 | KEAP1 (0.85) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28369102 | 0.85 | KEAP1 (0.87) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28369101 | 0.85 | KEAP1 (0.87) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28369671 | 0.82 | PHGDH (0.69) | PHGDHKEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL28373194 | 0.82 | PHGDH (0.81) | PHGDHKEAP1NFE2L2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | PEKING UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2020-02-20 | — | — | US | disclosed |
| CN-106562951-B | Furan D-3-phosphoglycerate dehydrogenase allosteric inhibitor and its application | 北京大学 | 2020-02-11 | — | — | CN | disclosed |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | MDH2, MDH1, DLD | PHGDH 4/4885KEAP1 705/4885NFE2L2 1212/4885 |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | PHGDH 4/4885KEAP1 705/4885NFE2L2 1212/4885 |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | PHGDH 4/4885KEAP1 705/4885NFE2L2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.